Document:

EX-10.35

 Exhibit 10.35 

 

					
		  		  	 

 Project No.: 858392 / 30000 MAB/SAH

 

 Funding agreement 

concluded between 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as a funding entity 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Commercial Register No.: 354305m 

as a recipient. 
 § 1
Granting of the funding 
  

	1.1	On the basis of the funding application submitted on 08/23/2016 via eCall (“KLIPHA: Phase 2 efficacy study with ASN100 for the prevention of Staphylococcus aureus pneumonia in ventilated patients” and on the
basis of the special decision of the advisory committee brought forward in the meeting held on 02/01/2017, funding is granted for the following undertakings: 

  

			
	Project number:	  	858392
	eCall number:	  	8749999
	Project name (subject of the contract):
		  	KLIPHA Phase 2 efficacy study with ASN100 for the prevention of Staphylococcus aureus pneumonia in ventilated patients
	Program:	  	Basic program

  

							
		  		  		  	/2
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 2

	  		  	 

 Project No.: 858392 / 30000

  

 § 2 Project term 

 

	2.1	The overall term of the project begins on 11/01/2016 and ends on 10/31/2018. 

  

	2.2	The funding of the overall undertaking by FFG shall depend on the results presented in the submitted reports, on further compliance with assessment and decision criteria, on the budget placed at the disposal of the
funding entity as well as on the new positive decision on funding. 

 § 3 Period of funding 

 

	3.1	The respective period of funding the undertaking commences on 11/01/2016 as an acceptance deadline and ends on 10/31/2018. 

§ 4 Type and amount of funding 
  

	4.1	The funding shall be realized in the following form for the period of funding stipulated in § 3: 

  

					
	 Funding form
	  	Amount
up to maximum	 
	 Loan of FFG
	  	 	EUR         1,500,000.00	 

  

			
	Conditions of the loan	  	
	Interest rate	  	0.75 % per annum on a current account
	Repayment deadline:	  	on 03/31/2023
	Repayment amount:	  	EUR 1,500,000.00
	Collection of the interests and loan:	  	by virtue of direct debit mandates
	Determination of the interests:	  	on a semi-annual basis and retroactively or at the repayment deadline

  

	4.2	The funding rate for the undertaking amounts to 50.0 % of the costs of the project, which must be proven and fundable. The remaining financing of the costs of the project must take place via the recipient.
According to the planning data, the cash value of the funding amounts to EUR 201,665.00, or 6.7 % of the fundable costs of the project as per Item 5.1. 

  

	4.3	The maximum intensity of subsidies according to the applicable framework of the Union for government subsidies for supporting research, development and innovation amounts to 45.0 %. 

 

	4.4	The funding shall be reduced proportionally if the fundable costs of the project should turn out to be below the limit. 

  

	4.5	The fundable costs of the project as per § 5 as well as costs incurred due to interim and final accounting shall not constitute an acknowledgement of the costs prior to an audit to be carried out by FFG. The final
amount of the acknowledged costs of the overall project as well as the funding shall only be determined after the project has been finalized within the framework of accounting control. 

  

							
		  		  		  	/3
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 3

	  		  	 

 Project No.: 858392 / 30000

  

 § 5 Fundable costs 

5.1 The following fundable costs of the project have been taken as a basis for the funding: 

 

					
	 Personnel costs
	  	EUR  	516,399.00	 
	 Costs of equipment and material
	  	EUR  	225,000.00	 
	 Third-party performance
	  	EUR  	2,237,476.00	 
	 Travel costs
	  	EUR  	21,125.00	 
		  	  
	  
	 
	 Total fundable costs
	  	EUR  	3,000,000.00	 

  

	5.2	All costs actually incurred within the framework of the project and in addition (to the usual operating expenditure) during the period of funding as per § 3 shall be deemed as fundable. Other amending provisions
pertaining to the fundable costs can be found in the FFG Directive “KMU”, the guidelines on costs as well as guidelines pertaining to individual project of experimental development (each in the version indicated below in Item 14.1).

  

	5.3	Relevant changes in the structure of the costs require the prior written approval of FFG. 

  

	5.4	The turnover tax on the costs of fundable performance shall not be considered as fundable. However, insofar as this turnover tax must actually be borne by the recipient and if this can be proven, and if this should
result in the recipient not being entitled to any withholding tax deduction, these shall be taken into consideration as a fundable cost component. 

The funding provided by the funding entity constitutes a grant which is not subject to turnover tax, due to the fact that no exchange of
services takes place, but rather a public interest in the realization of the research project. 
 The amount of the funding represents a
gross amount. Another, separate settlement of any potential fees and taxes by FFG – irrespectively of the reasons for it – is precluded. 

The loan interests / liability commissions are subject to the exemption from the obligation to pay turnover tax, in accordance with § 6
Para. 1 Clause 8 of UStG (Umsatzsteuergesetz [Austrian Turnover Tax Act]). 
  

	5.5	Should the amortization period for one item (§ 285 of ABGB (Allgemeines bürgerliches Gesetzbuch [Austrian General Civil Code])) which has been acquired for the purpose of realizing the project takes
longer than the period of funding, the amortization costs shall be considered as fundable in accordance with the provisions laid out in the guidelines pertaining to an individual project of experimental development as well as in the guidelines on
costs (each in the version indicated below in Item 14.1). 

  

	5.6	The funds of the funding entity may not be utilized for formation of reserves or accruals pursuant to the Austrian Income Tax Act [Einkommensteuergesetz] as of 1988, BGBl. (Bundesgesetzblatt [Austrian
Legal Gazette]) No. 400/1988. The funds may only be utilized for the services and objectives described in the funding application. 

  

	5.7	The costs of contract preparation or bank transfer fees incurred on the part of the recipient or his/her internal partner must be borne by him and do not constitute fundable costs. 

 

	5.8	The funding entity shall reserve the right to defer the disbursement of a funding, to reduce it or to suspend it if and as long as there are circumstances which prevent the proper realization of the funded undertaking
(e.g. the proof of the costs incurred has not been produced in an appropriate form). 

  

							
		  		  		  	/4
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 4

	  		  	 

 Project No.: 858392 / 30000

  

 § 6 Conditions and requirements 

 

	6.1	Project-specific special conditions and requirements 

  

	 	1.	A safe financing concept for the undertaking must be submitted within the period of 12 weeks after the date on which the contract has been issued, before the first installment has been disbursed. 

 

	 	2.	The costs of Ms. Nagy and Ms. Zettl shall not be funded. 

  

	 	3.	Clinical studies may only be funded until the amount of total costs reaches the amount of 3 million Euros. Accordingly, third-party costs shall be reduced as a general rule. 

 

	 	4.	Funding depends on the existence of a development location including personnel and IP rights until 03/31/2023 at the earliest. 

  

	6.2	The original undersigned funding agreement must be sent back within the period of 4 weeks following the receipt thereof by the funding entity at the latest. 

 

	6.3	The recipient shall be obligated to inform the funding entity – in the course of the planned reporting at the latest—of all applied and/or approved public funding which pertains to the project, be it directly
or indirectly, as from the time at which this funding agreement has been undersigned. 

 § 7 Disbursement of the
funding 
  

	7.1	The aforementioned funding shall be transferred according to the following payment plan: 

  

	7.2	The funds shall be transferred to the following bank account of the recipient: 

  

			
	Account holder:	  	ARISANIS Biosciences GmbH
	Bank designation:        	  	
	IBAN:	  	
	BIC / SWIFT:	  	

 § 8 Reporting obligations 

 

	8.1	The recipient must submit reports to FFG in accordance with Section 3 of General Terms and Conditions of Funding with respect to the realization of the funded undertaking by means of submitting specialist reports
(interim and final reports) and accounts. 

  

	  	A specialist interim report and interim accounting must be submitted within the period of one month following the reporting deadlines stipulated in the funding agreement. 

 

	  	A specialist final report and final accounting must be submitted within the period of three months following the end of the period of funding stipulated in the contract at the latest. 

 

	  	Reports and accounts must be submitted via eCall (https://ecall.ffg.at). The forms stored in the eCall must be used by all means. Further documents must be submitted to FFG upon their request. 

 

	8.2	In case prototypes are being funded, the recipient must submit reports to FFG with respect to the continuation or further utilization of the prototype / prototypes. 

  

							
		  		  		  	/5
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 5

	  		  	 

 Project No.: 858392 / 30000

  

 § 9 Amendments to the contract 

 

	9.1	Amendments to this contract may only be carried out expressly in writing. This shall also apply for annulment of this provision. 

  

	9.1	Subsequent amendments to the stipulated provisions and requirements may – insofar as necessary – be carried out under special circumstances by mutual consent in the form of an additional ancillary agreement
after the advisory committee has reached a positive decision in this respect. 

 § 10 Liability 

 

	10.1	The recipient shall be unrestrictedly liable vis-à-vis FFG for compliance with all contractual provisions. The recipient shall also
be liable for the conduct of third parties assignable to the recipient (e.g. owners, company bodies etc.). The recipient shall indemnify and hold FFG harmless from and against the claims of third parties. 

§ 11 Severability clause 
  

	11.1	Should one provision of this funding agreement be ineffective, the effectiveness of the remaining provisions of the funding agreement shall remain unaffected thereby. The contractual parties are obligated to replace an
ineffective provision by another provision which serves the purpose of this funding agreement to the greatest extent possible. 

§ 12 Applicable law 
  

	12.1	This contract and all its annexes are subject to the law of the Republic of Austria under exclusion of the laws rules of Austrian IPRG (Gesetze zum Internationalen Privatrecht [Legislation on private
international law]). 

 § 13 Place of legal jurisdiction 

 

	13.1	The competent court in Vienna shall have jurisdiction for all legal disputes which should arise from the funding grant. FFG shall reserve the right to sue the recipient at their place of jurisdiction as well.

 § 14 Integral parts of the contract 
  

	14.1	The following documents constitute integral parts of the funding agreement: 

  

	 	•	 	the funding application submitted via eCall (“KLIPHA: Phase 2 efficacy study with ASN100 for the prevention of Staphylococcus aureus pneumonia in ventilated patients”) in the version as of 11/21/2016

  

	 	•	 	General Terms and Conditions of Funding for Funding Agreements in their respectively applicable version (Version 2015) 

  

	 	•	 	Guidelines for individual project of experimental development, Version 3.2 

  

	 	•	 	Guidelines on the costs, Version 2.0 

  

							
		  		  		  	/6
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 6

	  		  	 

 Project No.: 858392 / 30000

  

	14.2	The following is in particular taken as a legal basis for this funding agreement: 

  

	 	•	 	Establishment Act of Österreichische Forschungsförderungsgesellschaft mbH [Act on Structural Reform of Research Funding] in the respective applicable version 

 

	 	•	 	Union’s framework for public subsidies for funding research, development and innovation ((ABl. (Auswahlblatt [Extract Sheet]) C 198 as of 06/27/2014) 

 

	 	•	 	Directive (EU) No. 651/2014 of the Committee as of June 17,2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty on the Functioning
of the European Union (AGVO (Allgemeine Gruppenfreistellungsverordnung [General Block Exemption Ordinance]) 2014) 

  

	 	•	 	Directive for Österreichische Forschungsförderungsgesellschaft mbH on funding the applied research, development and innovation (FFG Directive “KMU”), Ref. No: BMVIT-609.986/0012-III/I2/2014 and BMWFW-98.310/0102-C1/10/2014) – This directive was enacted on the basis of AGVO 2014
with the European Commission. 

  

							
		  		  		  	/7
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of Vienna	  		  	
		  		  		  	

					
	  
  Page
 7

	  		  	 

 Project No.: 858392 / 30000

  

 The recipient confirms that they are familiar with all integral parts of the contract and accept them without
any restrictions and acknowledges that non-compliance with the stipulated contractual provisions can lead to a potential recall of the funds. 

The recipient confirms that there are no pending recall order of the European Commission and a potential recession of incompatible funding is precluded. 

The recipient agrees to utilization of the data listed in Article 9, Para. 1 of AGVO (EU Ordinance No. 651/2014) Annex III for the purpose of publishing
the information, insofar as the cash value of the funding (gross subvention equivalent) exceeds the amount of EUR 500,000.00. 
 On behalf of the funding
entity: 
 Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

In Vienna, on 02/13/2017 
 [seal]
Österreichische Forschungsförderungsgesellschaft mbH (FFG) [emblem] 
  

					
	 /s/ Dr. Henrietta Egerth-Stadlhuber
	  		  	 /s/ Dr. Klaus Pseiner

	Dr. Henrietta Egerth-Stadlhuber	  		  	Dr. Klaus Pseiner
	Managing Director	  		  	Managing director

 Funding recipient 

        Vienna                 
           , on     3/23/2017             

			
		  	ARSANIS
		  	Biosciences GmbH
		  	MarxBox
	 /s/ Dr. Eszter Nagy
	  	Helmut-Qualtinger-Gasse 2
	 (please write the company name, names and functions in block letters, company seal)

 
 Dr. Eszter Nagy

Managing Director
	  	1030 Vienna

 Annexes: 
 Directive for
Österreichische Forschungsförderungsgesellschaft mbH on funding the applied research, development and innovation (FFG Directive “KMU”) 

via link: https://www.ffg.at/recht-finanzen/rechtsgrundlagen 

General Terms and Conditions of Funding for Funding Agreements in the applicable version (Version 2015) 

Guidelines for individual project of experimental development, Version 3.2 

Guidelines on the costs, Version 2.0 

  

							
		  		  		  	
	Österreichische	  	Tel: +43 (0) 5 7755 – 0	  		  	
	Forschungsförderungsgesellschaft mbH	  	Fax: +43 (0) 5 7755 – 97900	  		  	
	Sensengasse 1	  	www.ffg.at, office@ffg.at	  		  	
	1090 Vienna	  	FN 252263a Commercial Court of ViennaEX-10.36

 Exhibit 10.36 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (“Agreement”) is made as of
[                    ], 20[        ] by and between Arsanis, Inc., a Delaware corporation (the
“Company”), and [                    ] (“Indemnitee”)[ and shall be effective as of the effectiveness of a Registration Statement
on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock]. 

RECITALS 
 WHEREAS, highly
competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks
of claims and actions against them arising out of their service to and activities on behalf of the corporation; 
 WHEREAS, the Board of
Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving
the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given
current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises
are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Certificate of Incorporation
of the Company (as the same may be amended from time to time, the “Certificate of Incorporation”) requires indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the
General Corporation Law of the State of Delaware (the “DGCL”). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts
may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such
persons; 
 WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the
best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on
behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant
thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 

 [WHEREAS, Indemnitee is a representative of [•] [and its affiliated investment funds] (the
“Fund”), and has certain rights to indemnification and/or insurance provided by the Fund which Indemnitee and the Fund intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the
Company’s acknowledgement and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve on the Board;] 

WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present
circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service
for or on behalf of the Company on the condition that he be so indemnified. 
 NOW, THEREFORE, in consideration of the premises and the
covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: 
 Section 1. Services to the
Company. Indemnitee agrees to serve as a [officer] [director] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in
which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and
Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company (or any of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without
cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect
to service as a director or officer of the Company, by the Certificate of Incorporation, the Company’s By-laws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after
Indemnitee has ceased to serve as an [officer] [director] of the Company, as provided in Section 16 hereof. 
 Section 2.
Definitions. As used in this Agreement: 
 (a) References to “agent” shall mean any person who is or was a director,
officer, or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of
another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company. 

(b) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the
following events: 

  
 - 2 - 

 i. Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the
Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifty (50%) or more of the combined voting power of the Company’s then outstanding securities unless the change in relative Beneficial
Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors; 

ii. Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this
Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections
2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; 

iii. Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or its ultimate parent, as applicable) more than 51% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a
majority of the board of directors or other governing body of such surviving entity or its ultimate parent, as applicable; 
 iv.
Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and 

v. Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of
Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement. 

For purposes of this Section 2(b), the following terms shall have the following meanings: 

(A) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time. 

(B) “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however,
that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the
Company in substantially the same proportions as their ownership of stock of the Company. 

  
 - 3 - 

 (C) “Beneficial Owner” shall have the meaning given to such term in
Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the
Company with another entity. 
 (c) “Corporate Status” describes the status of a person who is or was a director, officer, employee
or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust or other enterprise which such person is or was serving at the request of the Company. 

(d) “Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding in respect of
which indemnification is sought by Indemnitee. 
 (e) “Enterprise” shall mean the Company and any other corporation, limited
liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary. 

(f) “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts and other
professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed
receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating,
being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium,
security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation,
enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance
with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in
settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 
 (g) “Independent Counsel” shall mean a law
firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party
(other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification
hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the
Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any
and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

  
 - 4 - 

 (h) The term “Proceeding” shall include any threatened, pending or completed action,
suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the
Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him (or a failure to take action by him) or of any action (or
failure to act) on his part while acting pursuant to his Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can
be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph. 

(i) Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise
tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services
by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants
and beneficiaries of an employee benefit plan shall be deemed to have acted in manner “not opposed to the best interests of the Company” as referred to in this Agreement. 

Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this
Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee
shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of
such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a
manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement
shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the By-laws, vote of its stockholders or disinterested directors or applicable law. 

  
 - 5 - 

 Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company
shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.
Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue
or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any
claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court (as hereinafter defined) or any court in which the Proceeding was brought
shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. 

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of
this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter
therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or
otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each
successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice,
shall be deemed to be a successful result as to such claim, issue or matter. 
 Section 6. Indemnification For Expenses of a
Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any
Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. 

Section 7. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. 

Section 8. Additional Indemnification. 

(a) Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable
law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement
(including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the
Proceeding. 

  
 - 6 - 

 (b) For purposes of Section 8(a), the meaning of the phrase “to the fullest extent
permitted by applicable law” shall include, but not be limited to: 
 i. to the fullest extent permitted by the
provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and 

ii. to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of
this Agreement that increase the extent to which a corporation may indemnify its officers and directors. 
 Section 9.
Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee: 

(a) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with
respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or 
 (b) for (i) an accounting of
profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory
law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as
required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the
payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or 

(c) except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by
Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any
Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. 

Section 10. Advances of Expenses. Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)),
the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such advancement shall be made within thirty
(30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be
made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 14(d), advances
shall include any and all reasonable Expenses incurred pursuing an 

  
 - 7 - 

 
action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for
advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined
that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is
excluded pursuant to Section 9. 
 Section 11. Procedure for Notification and Defense of Claim. 

(a) Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or
advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts
underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is
reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from
any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company
shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. 

(b) The Company will be entitled to participate in the Proceeding at its own expense. 

Section 12. Procedure Upon Application for Indemnification. 

(a) Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with
respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or
(ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of
the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which
shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days
after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable
advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs

  
 - 8 - 

 
or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company
(irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to
any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. 

(b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a)
hereof, the Independent Counsel shall be selected as provided in this Section 12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee
advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in
which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within
ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted
only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of
such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless
and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to
Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall
have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the
person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to
Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 13. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this
Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.
Neither the failure of the 

  
 - 9 - 

 
Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the
circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a
defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 
 (b) Subject to
Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after
receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification,
absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a
prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person,
persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that
the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen
(15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five
(75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for
such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of
this Agreement. 
 (c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or
conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that
Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his
conduct was unlawful. 
 (d) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if
Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the
advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The
provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. 

  
 - 10 - 

 (e) The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner,
managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 

Section 14. Remedies of Indemnitee. 

(a) Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been
made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, 6 or 7 or the last
sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten
(10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable,
or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court
of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American
Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this
Section 14(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose
Indemnitee’s right to seek any such adjudication or award in arbitration. 
 (b) In the event that a determination shall have been made
pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo
trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving
Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. 
 (c) If a determination shall have been made
pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a
misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such
indemnification under applicable law. 

  
 - 11 - 

 (d) The Company shall, to the fullest extent not prohibited by law, be precluded from asserting
in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator
that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation,
enforcement or defense of Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company
shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not
prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and
officers’ liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such
indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater. 

(e) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this
Agreement shall be required to be made prior to the final disposition of the Proceeding. 
 Section 15. Non-exclusivity; Survival of Rights; Insurance; Subrogation. 
 (a) The rights of indemnification and
to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of
Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision,
permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater
benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder
or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or
policies. If, at the time of the receipt of a notice of a claim pursuant to the 

  
 - 12 - 

 
terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to
the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of
such Proceeding in accordance with the terms of such policies. 
 (c) In the event of any payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the
Company to bring suit to enforce such rights. 
 (d) The Company shall not be liable under this Agreement to make any payment of amounts
otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise. 

(e) The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company
as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount
Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust or other enterprise. 

Section 16. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years
after the date that Indemnitee shall have ceased to serve as a [officer] [director] of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of
indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant
to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of
the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse,
assigns, heirs, devisees, executors and administrators and other legal representatives. 
 Section 17. Severability. If any
provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without
limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and
shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto;
and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

  
 - 13 - 

 Section 18. Enforcement. 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes and
replaces all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof, including any indemnification agreement previously entered into between the Company and the
Indemnitee; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the By-laws and applicable law, and shall not be deemed a substitute therefor, nor
to diminish or abrogate any rights of Indemnitee thereunder. 
 Section 19. Modification and Waiver. No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall
any waiver constitute a continuing waiver. 
 Section 20. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company
in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The
failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise. 

Section 21. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and
shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the
third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission,
with receipt of oral confirmation that such transmission has been received: 
 (a) If to Indemnitee, at the address indicated on the
signature page of this Agreement, or such other address as Indemnitee shall provide to the Company. 
 (b) If to the Company to 

Arsanis, Inc. 
 890 Winter
Street, Suite 230 
 Waltham, MA 02451-1472 

Attn: Chief Financial Officer 
 or to any other
address as may have been furnished to Indemnitee by the Company. 

  
 - 14 - 

 Section 22. Contribution. To the fullest extent permissible under applicable law, if
the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the
circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding;
and/or (ii) the relative fault of the Company (and its other directors, officers, employees and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s). 

Section 23. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed
by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the
Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware
Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding
arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably RL&F Service Corp., 920 North King Street, 2nd Floor, Wilmington, New Castle County, Delaware 19801 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding
against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and
(v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 

Section 24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. 
 Section 25. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun
where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 

[Remainder of Page Intentionally Left Blank] 

  
 - 15 - 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year
first above written. 
  

			
	 ARSANIS, INC.
  

By:
                                         
                                         
  
 Name:
                                         
                                       

Title:
                                         
                                         
  
	  	 INDEMNITEE
  

By:
                                         
                                         
  
 Name:
                                         
                                         
  
 Address:
                                         
                                         
  

                          
                                         
                                 

                          
                                         
                                 

 Signature Page to Arsanis Indemnification Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]